File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Clinical experiences with bisphosphonate-induced osteochemonecrosis of the jaws: A new entity for clinicians

TitleClinical experiences with bisphosphonate-induced osteochemonecrosis of the jaws: A new entity for clinicians
Authors
Issue Date2006
Citation
Swiss Medical Weekly, 2006, v. 136 n. 31-32, p. 504-509 How to Cite?
AbstractQuestion: Bisphosphonates are frequently used drugs in the adjuvant therapy of bone metastases and tumour-induced hypercalcaemia, but also for osteoporosis or Pagets disease. Several publications within the last three years considered osteonecrosis of the jaws to be connected with bisphosphonate therapy. Until today possible treatment strategies contain antibiotics, hyperbaric therapy and operative treatment. The tendency of healing however seems to be extremely poor. All clinicians should be aware of this new kind of side effect of bisphosphonate therapy. Methods: 14 patients with this new kind of osteonecrosis were admitted to the department of Cranio-Maxillofacial Surgery of the University Hospital of Zurich. 8 men and 6 women all received bisphosphonates for cancer therapy. A complete analysis of patients' data was performed. Results: Of 14 patients in 7 the underlying disease was multiple myeloma. In one patient it was prostate cancer and in all female patients it was breast cancer. All of them had prior dental treatment and showed inflammatory signs and bacterial colonisation with localisation in the upper or lower jaw or in both. Conclusion: The infectious part of the bisphosphonate-induced osteonecrosis (ONJ) is considered to be more important than thought before. We presume that antimicrobial treatment is of utmost importance in the treatment of this kind of osteonecrosis. Patients with current or previous bisphosphonate therapy should be treated multidisciplinary to assure ideal prevention and treatment.
Persistent Identifierhttp://hdl.handle.net/10722/154426
ISSN
2015 Impact Factor: 1.549
2015 SCImago Journal Rankings: 0.621
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorDannemann, Cen_US
dc.contributor.authorGrätz, KWen_US
dc.contributor.authorZwahlen, Ren_US
dc.date.accessioned2012-08-08T08:25:15Z-
dc.date.available2012-08-08T08:25:15Z-
dc.date.issued2006en_US
dc.identifier.citationSwiss Medical Weekly, 2006, v. 136 n. 31-32, p. 504-509en_US
dc.identifier.issn1424-7860en_US
dc.identifier.urihttp://hdl.handle.net/10722/154426-
dc.description.abstractQuestion: Bisphosphonates are frequently used drugs in the adjuvant therapy of bone metastases and tumour-induced hypercalcaemia, but also for osteoporosis or Pagets disease. Several publications within the last three years considered osteonecrosis of the jaws to be connected with bisphosphonate therapy. Until today possible treatment strategies contain antibiotics, hyperbaric therapy and operative treatment. The tendency of healing however seems to be extremely poor. All clinicians should be aware of this new kind of side effect of bisphosphonate therapy. Methods: 14 patients with this new kind of osteonecrosis were admitted to the department of Cranio-Maxillofacial Surgery of the University Hospital of Zurich. 8 men and 6 women all received bisphosphonates for cancer therapy. A complete analysis of patients' data was performed. Results: Of 14 patients in 7 the underlying disease was multiple myeloma. In one patient it was prostate cancer and in all female patients it was breast cancer. All of them had prior dental treatment and showed inflammatory signs and bacterial colonisation with localisation in the upper or lower jaw or in both. Conclusion: The infectious part of the bisphosphonate-induced osteonecrosis (ONJ) is considered to be more important than thought before. We presume that antimicrobial treatment is of utmost importance in the treatment of this kind of osteonecrosis. Patients with current or previous bisphosphonate therapy should be treated multidisciplinary to assure ideal prevention and treatment.en_US
dc.languageengen_US
dc.relation.ispartofSwiss Medical Weeklyen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshBone Density Conservation Agents - Adverse Effectsen_US
dc.subject.meshBreast Neoplasms - Drug Therapy - Pathologyen_US
dc.subject.meshDiphosphonates - Adverse Effectsen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshJaw Diseases - Chemically Induced - Microbiology - Therapyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshMultiple Myeloma - Drug Therapy - Pathologyen_US
dc.subject.meshOsteonecrosis - Chemically Induced - Microbiology - Therapyen_US
dc.subject.meshProstatic Neoplasms - Drug Therapy - Pathologyen_US
dc.titleClinical experiences with bisphosphonate-induced osteochemonecrosis of the jaws: A new entity for cliniciansen_US
dc.typeArticleen_US
dc.identifier.emailZwahlen, R:zwahlen@hku.hken_US
dc.identifier.authorityZwahlen, R=rp00055en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid16947089en_US
dc.identifier.scopuseid_2-s2.0-33748778751en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33748778751&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume136en_US
dc.identifier.issue31-32en_US
dc.identifier.spage504en_US
dc.identifier.epage509en_US
dc.identifier.isiWOS:000240515800003-
dc.identifier.scopusauthoridDannemann, C=16030438700en_US
dc.identifier.scopusauthoridGrätz, KW=7005383755en_US
dc.identifier.scopusauthoridZwahlen, R=7004217269en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats